Error message

An illegal choice has been detected. Please contact the site administrator.

April 2020: Angiostamp800, A Bimodal Fluorescent & Photoacoustic Targeted Contrast Agent for Oncology

Presented by Jonathan Lavaud, PhD, Postdoctoral Researcher at Optimal Institute for Advanced Bioscience, Grenoble, France.

In vivo molecular imaging is a decisive tool in understanding the pathophysiological mechanisms involved in cancer development, metastasis, and drug development research. Specifically, photoacoustic imaging (PAI) has emerged as a new imaging modality that provides both high optical contrast and high ultrasound resolution at depth in living organisms.

PAI leverages differences in optical absorption in tissue components such as hemoglobin, lipids, melanin, collagen, and water and can also detect exogenous molecules. Although several inorganic contrast agents used for PAI have already been described, the need for fully biocompatible organic molecules that could be used for the in vivo PAI in cancer models still remains. Angiostamp800 is a novel molecular tracer that specifically targets a known membrane receptor involved in tumor angiogenesis.

In this webinar:

  • The usefulness of contrast agent based PAI for the exploration of cancer development - How to take advantage of PAI's ability to detect exogenous contrast agents targeting specific biomarkers of tumor development - The use of Angiostamp800 as a novel molecular tracer that can be used to non-invasively monitor liver metastasis progression in vivo
  • How Angiostamp800's bimodal properties enable the combination of PAI and fluorescence imaging and how this supports the interpretation and accuracy of the information extracted from photoacoustic imaging for the investigation of tumor development and metastatic
  • Q&A Session